Early Detection Research Network


This biomarker is also known as:
  • alternative macrophage activation-associated CC chemokine 1,
  • AMAC-1,
  • small inducible cytokine subfamily A (Cys-Cys), member 18, pulmonary and activation-regulated,
  • dendritic cell chemokine 1,
  • pulmonary and activation-regulated chemokine,
  • Alternative macrophage activation-associated CC chemokine 1,
  • AMAC1,
  • Dendritic cell chemokine 1,
  • chemokine (C-C), dendritic,
  • chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated),
  • Macrophage inflammatory protein 4,
  • SCYA18,
  • MIP-4,
  • Small-inducible cytokine A18,
  • small inducible cytokine A18,
  • CKb7,
  • CCL18,
  • small-inducible cytokine A18,
  • C-C motif chemokine 18,
  • CC chemokine PARC,
  • PARC,
  • CC chemokine ligand 18,
  • MIP4,
  • DC-CK1,
  • macrophage inflammatory protein 4,
  • DCCK1,
  • Pulmonary and activation-regulated chemokine,


From NCBI Gene: This antimicrobial gene is one of several Cys-Cys (CC) cytokine genes clustered on the q arm of chromosome 17. Cytokines are a family of secreted proteins involved in immunoregulatory and inflammatory processes. The CC cytokines are proteins characterized by two adjacent cysteines. The cytokine encoded by this gene displays chemotactic activity for naive T cells, CD4+ and CD8+ T cells and nonactivated lymphocytes, but not for monocytes or granulocytes. This chemokine attracts naive T lymphocytes toward dendritic cells and activated macrophages in lymph nodes. It may play a role in both humoral and cell-mediated immunity responses. [provided by RefSeq, Sep 2014]


There are no datasets associated with this biomarker.

QA State: Curated
Type: Protein
HGNC Name: CCL18

The following organs have data associated with this biomarker…


Phase: Two
QA State: Curated


CCL18 has been described in the literature as a potential biomarker for ovarian, bladder, breast, and colorectal cancer. CCL18 has not been identified previously in serum as a lung cancer biomarker, but it was observed up-regulated in lung cancer in the aptamer proteomic technology study (Ostroff et al, 2010).

Performance Comment

CCL18, also known as MIP-4, is a member of a 12 protein panel that can discriminate NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.


Phase: One
QA State: Under Review


Performance Comment

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

No associated publications found.